REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.

Original reporting
Published Nov 19, 2026, 4:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 4:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis — source image
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The FDA approval is a pivotal regulatory milestone for REGN’s neurology pipeline, supported by Phase 3 NIMBLE efficacy at week 24 and an outlined safety framework via boxed warning and REMS distribution.

02

Market read

Traders can reprice REGN’s neurology and RNAi exposure immediately due to a first-in-class siRNA approval, with quantified efficacy and defined safety constraints.

03

What to watch

The article does not quantify expected patient penetration, pricing, or uptake; traders may need to wait for post-approval guidance, payer coverage signals, and real-world safety/REMS logistics.

Relevance 7/10Novelty 4/10Timing: FDA approval reported today, after-hours/late-session read-through for biotech positioning

Background

Livsayis (cemdisiran) is a C5-directed siRNA therapy intended to reduce terminal complement activation, a key driver in generalized myasthenia gravis.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron said the FDA approved Livsayis (cemdisiran) for anti-AChR antibody-positive generalized myasthenia gravis, based on positive Phase 3 NIMBLE results.

Expected impact

Likely upward bias as the market prices in commercialization upside and de-risks the regulatory pathway for this asset.

Evidence & confidence

The article is a direct FDA approval with Phase 3 efficacy metrics and safety boxed warning details, which are typically material for valuation and positioning.

Market effects

Strengthens the RNAi/siRNA platform narrative in neurology and may lift sentiment for complement-targeting approaches in autoimmune neuromuscular disease.

Potential read-through to EU regulatory expectations for the same asset, with a stated decision window in 2H 2027.

Supports global commercialization expectations for RNAi therapeutics, with additional filings planned including Japan.

Counterpoint

The boxed warning for serious meningococcal infections and restricted REMS could limit uptake and increase monitoring costs, tempering near-term revenue expectations.

Key entities

  • Regeneron Pharmaceuticals

    Sponsor of Livsayis, receiving FDA approval for generalized myasthenia gravis in anti-AChR antibody-positive adults.

  • Livsayis (cemdisiran)

    C5-directed siRNA therapy approved for gMG, administered subcutaneously four times per year.

  • Alnylam

    Licensing partner for development, manufacturing, and commercialization under a worldwide licensing agreement.

  • FDA

    Approved Livsayis based on Phase 3 NIMBLE study results.

  • NIMBLE study

    Phase 3 trial providing the efficacy data cited for FDA approval.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.